Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2024-01-10 00:00:00 ET · period of report 2024-01-08 · accession 0000914475-24-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-10 | 2024-01-08+ | NBIX | GORMAN KEVIN CHARLES | CEO, Dir | M - OptEx | $19.59 | +167.9K | 561.8K | +43% | +$3.29M |
| DM | 2024-01-10 | 2024-01-08+ | NBIX | GORMAN KEVIN CHARLES | CEO, Dir | S - Sale+OE | $133.02 | -167.9K | 499.8K | -25% | -$22.33M |
| DM | 2024-01-10 | 2024-01-08+ | NBIX | GORMAN KEVIN CHARLES | CEO, Dir | M - OptEx | $19.59 | -167.9K | 0 | -100% | -$3.29M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-08 | M | A | 105,835 | $19.59 | 605,589 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-08 | S | D | 105,835 | $132.44 | 499,754 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.72 to $133.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2024-01-09 | M | A | 62,023 | $19.59 | 561,777 | D | — | — | |
| 4 | Common | Common Stock | 2024-01-09 | S | D | 62,023 | $134.01 | 499,754 | D | — | — | (F3) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.28 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F4) 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. |
| 5 | Derivative | Non-Qualified Stock Option | 2024-01-08 | M | D | 105,835 | $19.59 | 62,023 | D | $19.59 · — to 2024-01-16 | 105,835 Common Stock | (F5) The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024. |
| 6 | Derivative | Non-Qualified Stock Option | 2024-01-09 | M | D | 62,023 | $19.59 | 0 | D | $19.59 · — to 2024-01-16 | 62,023 Common Stock | (F5) The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024. |